References
- Chao EC, Henry RR. SGLT2 inhibition – a novel strategy for diabetes treatment. Nat Rev Drug Discov 2010;9:551-9
- Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose, dose-dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011;13:669-72
- Rosenstock J, Arbit D, Usiskin K, et al. Canagliflozin, an inhibitor of sodium glucose co-transporter 2 (SGLT2), improves glycemic control and lowers body weight in subjects with Type 2 diabetes on metformin [abstract #77-OR]. American Diabetes Association 70th Scientific Sessions, 25–29 June 2010, Orlando, FL, USA
- Rosenstock J, Polidori D, Zhao Y, et al. Canagliflozin, an inhibitor of sodium glucose co-transporter 2, improves glycemic control, lowers body weight, and improves beta-cell function in subjects with diabetes on background metformin [abstract]. 46th Annual Meeting of the European Association for the Study of Diabetes, 20–24 September 2010, Stockholm, Sweden
- Rosenstock J, Aggarwal N, Polidori D. et al. for the Canagliflozin DIA 2001 Study Group. Dose-ranging effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012 (in press)
- Nyirjesy P, Zhao Y, Ways K, et al. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 2012 (in press)
- Geerlings SE, Brouwer EC, Gaastra W, et al. Effect of glucose and pH on uropathogenic Escherichia coli: studies with urine from diabetic and non-diabetic individuals. J Med Microbiol 1999;48:535-9
- Zhanel GG, Nicolle LE, Harding GKM. Prevalence of asymptomatic bacteriuria and associated host factors in women with diabetes mellitus. Clin Infect Dis 1995;21:316-22
- Hammar N, Furahmand B, Gran M, et al. Incidence of urinary tract infection in patients with type 2 diabetes. Experience from adverse event reporting in clinical trials. Pharmacoepidemiol Drug Saf 2010;19:1287-92
- Geerlings SE, Stolk RP, Camps MJ, et al. Asymptomatic bacteriuria may be considered a complication in women with diabetes. Diabetes Mellitus Women Asymptomatic Bacteriuria Utrecht Study Group. Diabetes Care 2000;23:744-9
- Geerlings SE, Stolk RP, Camps MJ, et al. Diabetes Women Asymptomatic Bacteriuria Utrecht Study Group. Risk factors for symptomatic urinary tract infection in women with diabetes. Diabetes Care 2000;23:1737–41